Search

622 Result(s)
Sort by

Oncology

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
2018 Animal Welfare Medals

2018 Animal Welfare Medals

2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Open Innovation at Boehringer Ingelheim

Open Innovation at Boehringer Ingelheim

Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
World water day 2019

World water day 2019

Boehringer Ingelheim started a social project in Mexico to preserve the aquifer and to ensure the water supply for dog shelters. Rainwater collector will save 180,000 liters of rainwater every year.
cystic fibrosis phase II trial

cystic fibrosis phase II trial

The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Transforming Science Day

Transforming Science Day

How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
RE-LY-trial-publication-10-year-anniversary

RE-LY-trial-publication-10-year-anniversary

Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Thelaziosis dog eyeworms

Thelaziosis dog eyeworms

Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
founding-member-of-QUTAC

founding-member-of-QUTAC

Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
collaboration-kings-college-london

collaboration-kings-college-london

Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia